DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival

Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Fleischer, Thomas, Klajic, Jovana, Aure, Miriam Ragle, Louhimo, Riku, Pladsen, Arne V., Ottestad, Lars, Touleimat, Nizar, Laakso, Marko, Halvorsen, Ann Rita, Alnæs, Grethe I. Grenaker, Riis, Margit L.H., Helland, Åslaug, Hautaniemi, Sampsa, Lønning, Per Eystein, Naume, Bjørn, Børresen-Dale, Anne-Lise, Tost, Jörg, Kristensen, Vessela N.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352035/
https://ncbi.nlm.nih.gov/pubmed/27911866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13718
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars